CombinAble.AI News
2 articles
growth-positive
AION Labs Launches CombinAble.AI to Reduce Time and Cost of Targeted Antibody Design, Advancing Optimization of Drug Development
AION Labs, an Israel-based venture studio, has announced the launch of CombinAble.AI, a startup focused on accelerating the development of effective therapeutics. CombinAble.AI was formed after an AION Labs startup challenge aimed at developing an AI solution for optimizing therapeutic antibodies. The startup is developing a platform that integrates AI technology and computational methods for biomolecule simulations. The platform is expected to make the discovery and design of new biotherapeutics faster and more effective. CombinAble.AI is the latest startup launched by AION Labs, with the support of global pharmaceutical and technology leaders.
InvestmentExpand
growth-positive
סטארט-אפ בינה מלאכותית חדש בישראל: זה התחום בו יעסוק
AION Labs, a studio for developing start-ups at the forefront of the integration of artificial intelligence technologies in the biotech, computational biology, and medicine fields, has announced the launch of a new start-up, CombinAble.AI. The company was founded with the aim of finding technological solutions in the field of research and development of antagonists, in order to improve and accelerate the development processes of more effective drugs in the future. CombinAble.AI was established following a technological challenge distributed by AION Labs, which aimed to find solutions for integrating artificial intelligence in the examination and optimization of therapeutic antagonists.
Investment
